Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DERM

DERM - Dermira Inc Stock Price, Fair Value and News

$8.36-0.36 (-4.13%)
Market Closed

13/100

DERM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

13/100

DERM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$6.94

Target 3M

$7.81

Target 6M

$7.38

DERM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DERM Price Action

Last 7 days

-5.7%

Last 30 days

8.4%

Last 90 days

0.6%

Trailing 12 Months

105.9%

DERM RSI Chart

DERM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DERM Valuation

Market Cap

208.7M

Price/Earnings (Trailing)

-24.09

Price/Sales (Trailing)

3.51

EV/EBITDA

-37.14

Price/Free Cashflow

-53.07

DERM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$6.94

Target 3M

$7.81

Target 6M

$7.38

DERM Fundamentals

DERM Revenue

Revenue (TTM)

59.4M

Rev. Growth (Yr)

20.52%

Rev. Growth (Qtr)

17.47%

DERM Earnings

Earnings (TTM)

-8.7M

Earnings Growth (Yr)

3.14%

Earnings Growth (Qtr)

39.01%

DERM Profitability

Operating Margin

64.85%

EBT Margin

-14.38%

Return on Equity

-33.45%

Return on Assets

-10.17%

Free Cashflow Yield

-1.88%

DERM Investor Care

Shares Dilution (1Y)

23.94%

Diluted EPS (TTM)

-0.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202556.2M56.4M59.4M0
202480.0M77.7M57.8M56.1M
202362.6M61.5M79.9M79.2M
202275.7M78.7M75.2M73.7M
202149.2M53.8M58.5M63.1M
202000044.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Dermira Inc

DERM
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
 CEO
 WEBSITEhttps://journeymedicalcorp.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES20

Dermira Inc Frequently Asked Questions

DERM is the stock ticker symbol of Dermira Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Dermira Inc is 208.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check DERM's fair value in chart for subscribers.

The fair value guage provides a quick view whether DERM is over valued or under valued. Whether Dermira Inc is cheap or expensive depends on the assumptions which impact Dermira Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DERM.

As of Wed Jan 28 2026, DERM's PE ratio (Price to Earnings) is -24.09 and Price to Sales (PS) ratio is 3.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DERM PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Dermira Inc has provided -0.114 (multiply by 100 for percentage) rate of return.